The Medicines and Healthcare products Regulatory Agency (MHRA) has announced sweeping reforms to the UK’s clinical trials framework – the most significant overhaul in more than 20 years.
The changes are designed to make it faster and easier to approve and run clinical trials in the UK, reinforcing the country’s competitiveness at a time when global clinical research investment is increasingly mobile.
For sponsors, CROs and regulatory professionals, the reforms signal both opportunity and operational change.
Faster approvals through parallel review
A central feature of the reform is the introduction of parallel regulatory and ethics reviews. Instead of sequential assessment, applications will be reviewed simultaneously – a move the MHRA says could halve the time from submission to first patient enrolled, based on pilot data.
In addition:
- A maximum 30-day review period for new clinical trial applications is proposed
- A 10-day timeline for assessment of additional information requests
If implemented effectively, this represents a meaningful acceleration in start-up timelines – particularly important for late-phase, commercially sponsored trials where time-to-first-patient directly affects global programme delivery.
Mandatory transparency and results reporting
The reforms also strengthen transparency requirements. New trials will be legally required to:
- Register on a World Health Organisation (WHO) public registry
- Publish results within 12 months of study completion
For sponsors, this formalises expectations around public disclosure and aligns the UK more closely with global transparency standards. It also raises the bar on internal governance, data readiness and post-study reporting processes.
A response to declining commercial activity
The regulatory overhaul comes at a pivotal moment.
The UK Office of Life Sciences recently commissioned an independent review of the commercial clinical trials sector following reports of a 41% decline in new UK study starts between 2017 and 2021.
The UK has long been regarded as a global clinical research leader. However, NHS capacity pressures and post-pandemic recovery challenges have impacted site activation and recruitment – prompting concerns about long-term competitiveness.
Earlier this year, AstraZeneca publicly cited clinical trial capacity as a factor in its decision to locate a new facility in Ireland rather than the UK – a signal that regulatory agility and system performance now directly influence inward investment decisions.
Patient-centricity and diversity in recruitment
The reforms also place renewed emphasis on patient involvement and diversity.
The Association of the British Pharmaceutical Industry (ABPI) welcomed the MHRA’s commitment to clearer guidance on involving people with lived experience and improving recruitment diversity – without imposing quotas or arbitrary targets.
For regulatory and medical affairs teams, this suggests increasing expectations around inclusive protocol design, site selection strategies and patient engagement frameworks.
What this means for pharma and regulatory teams
If implemented at pace, these reforms could:
- Improve predictability in regulatory timelines
- Reduce administrative duplication
- Strengthen the UK’s appeal for global study allocation
- Enhance transparency and public trust in research
However, execution will be critical. Accelerated review timelines will require robust application quality, clear regulatory strategy and strong coordination between sponsors and investigators.
For the UK to reassert itself as a preferred destination for commercial clinical research, regulatory reform must be matched by operational readiness across the wider research ecosystem.
For industry stakeholders, the message is clear: the regulatory environment is shifting, and with it, the strategic calculus for UK-based trials.
Back to News + Insights